Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that predisposes affected individuals to an elevated risk of cardiovascular disease (CVD). The intricate interplay of traditional ...

THOUSAND OAKS, Calif., Oct. 27, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has completed trial design discussions through two Complex Innovative Trial Designs (CID) Pilot Program ...

Credit: Getty Images. CABA-201 is a 4-1BB-containing fully human CD19-CAR T cell therapy. The Food and Drug Administration (FDA) has granted Fast Track designation to CABA-201 for the treatment of ...

Lupus affects different people in different ways, and skin problems like rashes or sores are common. In a new study, people with systemic lupus erythematosus (SLE) were found to be at higher risk for ...

(RTTNews) - Adicet Bio, Inc. (ACET), a clinical stage biotechnology company, Wednesday said it received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for ADI-001 for the ...

Antibody. Illustration of an immunoglobulin antibody molecule. This Y-shaped molecule has two arms that can bind to specific antigens, for instance viral or bacterial proteins. In doing this it marks ...

Antibody-binding of blood dendritic cell antigen 2 (BDCA2), which is expressed exclusively on plasmacytoid dendritic cells, suppresses the production of type I interferon that is involved in the ...

Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand), showed efficacy in adults with active systemic lupus erythematosus (SLE) ...

Credit: Getty Images Understanding the underlying mechanisms and immunological dysfunction of SLE is essential to appreciate its diverse clinical manifestations and guide effective diagnosis and ...

Researchers investigated the patient factors that affect risk for mortality and lupus nephritis among patients with SLE. While the risk of developing lupus nephritis (LN) is higher among younger, ...

The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapies such as nipocalimab (Johnson & ...